Active, not recruitingPhase 2NCT05635708
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeiGene
- Principal Investigator
- Study DirectorBeiGene
- Intervention
- Tislelizumab(drug)
- Enrollment
- 400 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Valkyrie Clinical Trials, Los Angeles, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
- Providence Portland Medical Center, Portland, Oregon, United States
- The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
- Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
- Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
- Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia
- Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
- One Clinical Research, Nedlands, Western Australia, Australia
- St John of God Health Care, Subiaco, Western Australia, Australia
- Hospital de Amor Barretos, Barretos, Brazil
- Hospital Do Cancer de Londrina, Londrina, Brazil
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Brazil
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05635708 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital